Stanley Druckenmiller
ELVN icon

Stanley Druckenmiller’s Enliven Therapeutics ELVN Stock Holding History

Stanley Druckenmiller’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-947,405
Closed -$19.4M – 71
2025
Q3 		$19.4M Buy
947,405
+484,405
+105% +$9.76M 0.48% 50
2025
Q2 		$9.29M Buy
+463,000
New +$8.77M 0.23% 64

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Stanley Druckenmiller's ELVN Position: Q4 2025 in Review

Stanley Druckenmiller sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 947,405 shares — an estimated $19.4M sold.

Stanley Druckenmiller first reported a position in ELVN in Q2 2025 and held it in 2 quarters. The position peaked at $19.4M in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Stanley Druckenmiller reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stanley Druckenmiller sold 947,405 Enliven Therapeutics shares in Q4 2025, an estimated $19.4M.
  • Stanley Druckenmiller first reported a position in Enliven Therapeutics in Q2 2025 and held it in 2 quarters.
  • Stanley Druckenmiller's Enliven Therapeutics position peaked at $19.4M in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Duquesne Family Office's 13F filing for Q4 2025, filed 17 Feb 2026.